Clinic Owner Brief

Peptides Move Onto the FDA Advisory Calendar

A two-day FDA advisory committee meeting in July put several peptide-related bulk substances into a formal public discussion over the 503A bulks list. The agency's meeting page identifies substances under consideration, including BPC-157-related substances, KPV-related substances, TB-500, MOTS-C, semax and others. Background materials and a public docket were part of the process.

An advisory meeting is not the same thing as a final FDA rule. The committee gives nonbinding advice, and the presence of a substance on an agenda does not by itself settle its status. For a clinic planning a program months ahead, that distinction is the story. The question is not whether a familiar name appeared on a slide, but what action, if any, the agency subsequently takes and what rules apply meanwhile.

The meeting also shows why a static catalog makes a poor regulatory map. Operators who work with compounders need to separate nominations, interim policies, advisory recommendations and final agency action. The FDA meeting record is a starting point for following that sequence, not a blanket green or red light for any specific product.